The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Abstract
BACKGROUND: Blood levels of voriconazole, a first line therapy for invasive aspergillosis, may correlate with adverse events and treatment response. However, no randomized controlled studies have been conducted to evaluate the clinical utility of routine therapeutic drug monitoring (TDM) of voriconazole. This study aimed to determine whether routine TDM of voriconazole reduces drug adverse events or improves treatment response in invasive fungal infections. METHODS: This was a randomized, assessor-blinded, controlled, single center trial. One hundred ten adult patients were randomly assigned to TDM or non-TDM groups. In the TDM group, voriconazole dosage was adjusted (target range, 1.0-5.5 mg/L) according to the serum trough level measured on the fourth day after initiation of voriconazole. The non-TDM group received a fixed, standard dosage. Voriconazole-related adverse events were monitored, and treatment response was assessed three months after the initiation of therapy. RESULTS: Baseline characteristics including the CYP2C19 genotype were comparable between the two groups. While the incidence of adverse events was not different between the TDM group and the non-TDM group (both 42%; P = .97), the proportion of voriconazole discontinuation due to adverse events was significantly lower in the TDM group than in the non-TDM group (4% vs 17%; P = .02). A complete or partial response was observed in 81% (30 of 37) of patients in the TDM group compared to 57% (20 of 34) in the non-TDM group (P = .04). CONCLUSIONS: Routine TDM of voriconazole may reduce drug discontinuation due to adverse events and improve the treatment response in invasive fungal infections. CLINICAL TRIAL REGISTRATION: NCT00890708.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 2×
“Treatment response was categorized as complete, partial, stable, undetermined, or treatment failure [14].”
BackgroundPharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 475
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Walsh, T. J., Karlsson, M. O., Driscoll, T., Arguedas, A. G., Adamson, P., Saez-Llorens, X., Vora, A. J., Arrieta, A. C., Blumer, J., Lutsar, I., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2166-2172.2004 · Cited by 335
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-10 · Cited by 218
Trifilio, S., Pennick, G., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., Williams, S., Winter, J., Tallman, M., et al. (2007) · Cancer · doi:10.1002/cncr.22568 · Cited by 199
Adverse Reactions to Voriconazole
Boyd, A. E., Modi, S., Howard, S. J., Moore, C. B., Keevil, B. G., & Denning, D. W. (2004) · Clinical Infectious Diseases · doi:10.1086/424662 · Cited by 182
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S., Ortiz, R., Pennick, G., Verma, A., Pi, J., Stosor, V, Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180
Voriconazole concentrations and outcome of invasive fungal infections
Miyakis, S., van Hal, S. J., Ray, J., & Marriott, D. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02990.x · Cited by 159
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety
Purkins, L., Wood, N., Greenhalgh, K., Allen, M. J., & Oliver, S. D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01993.x · Cited by 149
Hallucinations during Voriconazole Therapy
Zonios, D. I., Gea‐Banacloche, J., Childs, R., & Bennett, J. E. (2008) · Clinical Infectious Diseases · doi:10.1086/588844 · Cited by 139
Ueda, K., Nannya, Y., Kumano, K., Hangaishi, A., Takahashi, T., Imai, Y., & Kurokawa, M. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0296-3 · Cited by 131
Matsumoto, K., Ikawa, K., Abematsu, K., Fukunaga, N., Nishida, K., Fukamizu, T., Shimodozono, Y., Morikawa, N., Takeda, Y., & Yamada, K. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.008 · Cited by 129
Therapeutic Drug Monitoring of Voriconazole
Brüggemann, R. J. M., Donnelly, J. P., Aarnoutse, R. E., Warris, A., Blijlevens, N. M. A., Mouton, J. W., Verweij, P. E., & Burger, D. M. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31817b1a95 · Cited by 126
Shimizu, T., Ochiai, H., Åsell, F., Shimizu, H., Saitoh, R., Hama, Y., Katada, J., Hashimoto, M., Matsui, H., Taki, K., et al. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.48 · Cited by 115
Lee, S., Kim, B., Nam, W. S., Yoon, S. H., Cho, J., Shin, S., Jang, I., & Yu, K. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010395510 · Cited by 107
Self-citationHepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
Levin, M.-D., den Hollander, J. G., van der Holt, B., Rijnders, B. J. A., van Vliet, M., Sonneveld, P., & van Schaik, R. H. N. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm330 · Cited by 86
Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation
Trifilio, S. M., Yarnold, P. R., Scheetz, M. H., Pi, J., Pennick, G. J., & Mehta, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01316-08 · Cited by 67
den Hollander, J. G. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl108 · Cited by 61
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Metadata
- Authors
- Park, W. B., Kim, N.-H., Kim, K.-H., Lee, S. H., Nam, W.-S., Yoon, S. H., Song, K.-H., Choe, P. G., Kim, N. J., Jang, I.-J., Oh, M.-D., & Yu, K.-S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-03
- Volume
- 55
- Issue
- 8
- Pages
- 1080-1087
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2149613723
- Cited by
- 399
- References
- 23
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.